NURIX THERAPEUTICS, INC. Net Income
NURIX THERAPEUTICS, INC. (NRIX) reported Net Income of -$89.53 million for the 3-month period ending 2026-05-31, per its 10-Q filed 2026-07-09.
Financial Statements › Income Statement
us-gaap:NetIncomeLoss · last filed 2026-07-09
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-05-31 was -$89.53M.
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2026-02-28 was -$87.17M.
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-11-30 was -$78.22M.
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for the quarter ending 2025-08-31 was -$86.42M.
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2025 was -$264.46M.
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2024 was -$193.57M.
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2023 was -$143.95M.
- NURIX THERAPEUTICS, INC. net income (loss) attributable to parent for fiscal 2022 was -$180.36M.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 12 month |
|---|---|---|---|---|
| 2026-05-31 | -$89.53M 10-Q · filed 2026-07-09 | -$176.71M 10-Q · filed 2026-07-09 | -$254.93M derived: sum of 3 quarters · filed 2026-07-09 | -$341.35M derived: sum of 4 quarters · filed 2026-07-09 |
| 2026-02-28 | -$87.17M 10-Q · filed 2026-07-09 | -$165.40M derived: sum of 2 quarters · filed 2026-07-09 | -$251.82M derived: sum of 3 quarters · filed 2026-07-09 | -$295.28M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-11-30 | -$78.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$164.64M derived: sum of 2 quarters · filed 2026-01-28 | -$208.11M derived: sum of 3 quarters · filed 2026-07-09 | -$264.46M 10-K · filed 2026-01-28 |
| 2025-08-31 | -$86.42M 10-Q · filed 2025-10-09 | -$129.88M derived: sum of 2 quarters · filed 2026-07-09 | -$186.24M 10-Q · filed 2025-10-09 | -$244.78M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-05-31 | -$43.46M 10-Q · filed 2026-07-09 | -$99.81M 10-Q · filed 2026-07-09 | -$158.36M derived: sum of 3 quarters · filed 2026-07-09 | -$207.32M derived: sum of 4 quarters · filed 2026-07-09 |
| 2025-02-28 | -$56.35M 10-Q · filed 2026-07-09 | -$114.90M derived: sum of 2 quarters · filed 2026-07-09 | -$163.86M derived: sum of 3 quarters · filed 2026-07-09 | -$208.40M derived: sum of 4 quarters · filed 2026-07-09 |
| 2024-11-30 | -$58.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$107.50M derived: sum of 2 quarters · filed 2026-01-28 | -$152.05M derived: sum of 3 quarters · filed 2026-01-28 | -$193.57M 10-K · filed 2026-01-28 |
| 2024-08-31 | -$48.96M 10-Q · filed 2025-10-09 | -$93.50M derived: sum of 2 quarters · filed 2025-10-09 | -$135.02M 10-Q · filed 2025-10-09 | -$176.98M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-05-31 | -$44.55M 10-Q · filed 2025-10-09 | -$86.06M 10-Q · filed 2025-07-09 | -$128.02M derived: sum of 3 quarters · filed 2026-01-28 | -$165.00M derived: sum of 4 quarters · filed 2026-01-28 |
| 2024-02-29 | -$41.52M 10-Q · filed 2025-10-09 | -$83.47M derived: sum of 2 quarters · filed 2026-01-28 | -$120.46M derived: sum of 3 quarters · filed 2026-01-28 | -$144.73M derived: sum of 4 quarters · filed 2026-01-28 |
| 2023-11-30 | -$41.96M derived: 10-K 12 month − 10-Q 9 month · filed 2026-01-28 | -$78.94M derived: sum of 2 quarters · filed 2026-01-28 | -$103.22M derived: sum of 3 quarters · filed 2026-01-28 | -$143.95M 10-K · filed 2026-01-28 |
| 2023-08-31 | -$36.98M 10-Q · filed 2024-10-11 | -$61.26M derived: sum of 2 quarters · filed 2024-10-11 | -$101.99M 10-Q · filed 2024-10-11 | -$148.71M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-05-31 | -$24.28M 10-Q · filed 2024-10-11 | -$65.01M 10-Q · filed 2024-07-11 | -$111.73M derived: sum of 3 quarters · filed 2025-01-28 | -$157.44M derived: sum of 4 quarters · filed 2025-01-28 |
| 2023-02-28 | -$40.73M 10-Q · filed 2024-10-11 | -$87.45M derived: sum of 2 quarters · filed 2025-01-28 | -$133.16M derived: sum of 3 quarters · filed 2025-01-28 | -$178.56M derived: sum of 4 quarters · filed 2025-01-28 |
| 2022-11-30 | -$46.72M derived: 10-K 12 month − 10-Q 9 month · filed 2025-01-28 | -$92.43M derived: sum of 2 quarters · filed 2025-01-28 | -$137.83M derived: sum of 3 quarters · filed 2025-01-28 | -$180.36M 10-K · filed 2025-01-28 |
| 2022-08-31 | -$45.71M 10-Q · filed 2023-10-12 | -$91.11M derived: sum of 2 quarters · filed 2023-10-12 | -$133.64M 10-Q · filed 2023-10-12 | -$171.34M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-05-31 | -$45.40M 10-Q · filed 2023-10-12 | -$87.93M 10-Q · filed 2023-07-13 | -$125.64M derived: sum of 3 quarters · filed 2023-10-12 | -$154.47M derived: sum of 4 quarters · filed 2023-10-12 |
| 2022-02-28 | -$42.53M 10-Q · filed 2023-10-12 | -$80.23M derived: sum of 2 quarters · filed 2023-10-12 | -$109.07M derived: sum of 3 quarters · filed 2023-10-12 | -$135.45M derived: sum of 4 quarters · filed 2023-10-12 |
| 2021-11-30 | -$37.70M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-09 | -$66.54M derived: sum of 2 quarters · filed 2023-02-09 | -$92.92M derived: sum of 3 quarters · filed 2023-02-09 | -$117.19M 10-K · filed 2023-02-09 |
| 2021-08-31 | -$28.84M 10-Q · filed 2022-10-06 | -$55.22M derived: sum of 2 quarters · filed 2022-10-06 | -$79.49M 10-Q · filed 2022-10-06 | -$99.41M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-05-31 | -$26.38M 10-Q · filed 2022-10-06 | -$50.66M 10-Q · filed 2022-07-07 | -$70.57M derived: sum of 3 quarters · filed 2022-10-06 | -$89.09M derived: sum of 4 quarters · filed 2022-10-06 |
| 2021-02-28 | -$24.27M 10-Q · filed 2022-10-06 | -$44.19M derived: sum of 2 quarters · filed 2022-10-06 | -$62.71M derived: sum of 3 quarters · filed 2022-10-06 | -$55.13M derived: sum of 4 quarters · filed 2022-10-06 |
| 2020-11-30 | -$19.91M 10-K · filed 2021-02-16 | -$38.43M derived: sum of 2 quarters · filed 2021-10-14 | -$30.85M derived: sum of 3 quarters · filed 2021-10-14 | -$43.24M 10-K · filed 2022-01-28 |
| 2020-08-31 | -$18.52M 10-Q · filed 2021-10-14 | -$10.94M derived: sum of 2 quarters · filed 2021-10-14 | -$23.33M 10-Q · filed 2021-10-14 | -$36.85M derived: sum of 4 quarters · filed 2021-10-14 |
| 2020-05-31 | $7.58M 10-Q · filed 2021-10-14 | -$4.81M 10-Q · filed 2021-07-13 | -$18.33M derived: sum of 3 quarters · filed 2021-10-14 | -$20.76M derived: sum of 4 quarters · filed 2021-10-14 |
| 2020-02-29 | -$12.39M 10-Q · filed 2021-10-14 | -$25.91M derived: sum of 2 quarters · filed 2021-10-14 | -$28.34M derived: sum of 3 quarters · filed 2021-10-14 | -$31.41M derived: sum of 4 quarters · filed 2021-10-14 |
| 2019-11-30 | -$13.52M 10-K · filed 2021-02-16 | -$15.95M derived: sum of 2 quarters · filed 2021-02-16 | -$19.01M derived: sum of 3 quarters · filed 2021-02-16 | -$21.70M 10-K · filed 2022-01-28 |
| 2019-08-31 | -$2.43M 10-K · filed 2021-02-16 | -$5.50M derived: sum of 2 quarters · filed 2021-02-16 | -$8.18M 10-Q · filed 2020-10-14 | |
| 2019-05-31 | -$3.07M 10-K · filed 2021-02-16 | -$5.75M derived: sum of 2 quarters · filed 2021-02-16 | ||
| 2019-02-28 | -$2.69M 10-K · filed 2021-02-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |